Feature
MOTS-c: Where the Evidence Ends
Studies offer clues about ageing and metabolism. What do they actually tell us about human health—and where does expert opinion take over?
Longevity Technology
Muna Therapeutics’ Alzheimer’s drug MNA-001 passes early safety trial
Muna reported initial tolerability and target-engagement findings for its experimental TREM2 drug. Patient benefit remains unproven.
Key takeaways
- MNA-001 was well tolerated in an early healthy-volunteer trial.
- Dose-dependent changes in soluble TREM2 biomarkers were reported.
- Biomarker shifts have not established clinical benefit in patients.
